Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-13-173941
Filing Date
2013-04-25
Accepted
2013-04-25 16:41:58
Documents
5
Effectiveness Date
2013-04-25

Document Format Files

Seq Description Document Type Size
1 DEFINITIVE ADDITIONAL MATERIALS d522367ddefa14a.htm DEFA14A 26869
2 GRAPHIC g522367notice_pg1.jpg GRAPHIC 75038
3 GRAPHIC g522367notice_pg2.jpg GRAPHIC 125678
4 GRAPHIC g522367notice_pg3.jpg GRAPHIC 45746
5 GRAPHIC g522367notice_pg4.jpg GRAPHIC 9873
  Complete submission text file 0001193125-13-173941.txt   381829
Mailing Address 395 OYSTER POINT BOULEVARD SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 395 OYSTER POINT BOULEVARD SUITE 400 SOUTH SAN FRANCISCO CA 94080 650-266-3500
SUNESIS PHARMACEUTICALS INC (Filer) CIK: 0001061027 (see all company filings)

IRS No.: 943295878 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 000-51531 | Film No.: 13783420
SIC: 2834 Pharmaceutical Preparations